References
- Blumenreich M S, Woodcock T M, Richman S P. A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies. Cancer 1985; 56: 256–258
- Phillips T L, Fu K K. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer 1976; 37: 1186–1200
- Kellie S J, Plowman P N, Malpas S S. Radiation recall and radiosensitization with alkylating agents. Lancet 1987; 1: 1149–1150
- Vegesna V, Withers H R, McBride W H. Adriamycin-induced recall of radiation pneumonitis and epilation in lung and hair follicles of mouse. Int J Radiat Oncol Biol Phys 1992; 23: 977–981
- Stelzer K J, Griffin T W, Koh W J. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer 1993; 71(4)1322–1325
- Wallenbom P A, III, Postma D S. Radiation recall supraglonitis. Arch Otolaryngol 1984; 110: 614–617
- Wiatrdk B J, Myer CM, III. Radiation recall supraglottitis in a child. Am J Otolaryngol 1991; 12: 227–229
- Yokel B K, Friedman K J, Farmer E R. Cutaneous pathology following etoposide therapy. J Cutan Pathol 1987; 14: 326–330
- DeSpain J D. Dermatologic toxicity. The Chemotherapy Source Book, MC Perry. Williams & Wilkins, Baltimore 1991; 537
- Raghavan V, Bloomer W, Merkel D. Taxol and radiation recall dermatitis. Lancet 1992; 341: 1354
- Parry B R. Radiation recall induced by tamoxifen. Lancet 1992; 340: 49, (letter)
- Schmid F A, Sirotnak F M, Otter G M. New folate analogs of the deaza-aminopterin series: Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some tumor xenografts in nude mice. Cancer Treat Rep 1985; 69: 551–553
- Kris M G, Knahan J J, Grab R J. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Res 1988; 48: 5573–5579
- Shum K Y, Kris M G, Gralla R J. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1988; 6: 446–450
- Verweij J, Schomagel J, DeMulder P. Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate. Cancer 1990; 66: 1910–1913
- Vandenberg T A, Pritchard K I, Eisenhauer E A. Phase II study of edatrexate as first-line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1993; 11: 1241–1244
- Bronner A K, Hood A F. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 1983; 9: 645–663
- Jolivet J, Landry L, Pinard M F. A phase I study of trimetrexate. an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169–172
- Weiss R B, James W D, Major W B. Skin reactions induced by trimetrexate. an analog of methotrexate. Investigat New Drugs 1986; 4: 159–163
- Calvert A H, Alison D L, Harland S J. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5.8-dideazafolic acid. CB3717. J Clin Oncol 1986; 4(8)1245–1252